Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro

A. T. McGown, G. Jayson, George Pettit, M. S. Haran, T. H. Ward, D. Crowther

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

This study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent tamoxifen caused a large synergistic enhancement of growth inhibition in P388 cells in vitro. The growth-inhibitory effects of bryostatin 1 in the presence of non-inhibitory concentrations of tamoxifen were increased by approximately 200-fold, whereas growth inhibition by tamoxifen in the presence of non-inhibitory concentrations of bryostatin 1 were increased over 30-fold. These data have been confirmed by isobologram analysis. The precise mechanism underlying this effect is unknown, although preliminary data implicating protein kinase C is presented. The magnitude of this synergistic effect, together with evidence of clinical responses seen when these agents were given sequentially in ovarian cancer, merits further study.

Original languageEnglish (US)
Pages (from-to)216-220
Number of pages5
JournalBritish Journal of Cancer
Volume77
Issue number2
DOIs
StatePublished - Jan 1 1998

Keywords

  • Bryostatin
  • Protein kinase C
  • Synergy
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro'. Together they form a unique fingerprint.

  • Cite this